Incidence and Risk Factors of Hyperglycemia in Severe Multisystem Inflammatory Syndrome in Children: A Retrospective Case-Control Study

Abstract

Objective Multisystem inflammatory syndrome in children (MIS-C) patients might be at risk for hyperglycemia and associated complications. Herein, we aimed to determine the incidence of hyperglycemia, understanding the underlying risk factors in MIS-C patients.

Methods All MIS-C patients were retrospectively evaluated and compared according to the presence of hyperglycemia and the need of insulin. Inflammatory markers and body mass index Z-scores were also compared.

Results The median age of the patients with hyperglycemia was higher than those without (p = 0.001). Disease severity scores of patients with hyperglycemia were higher. Procalcitonin levels of patients with hyperglycemia were higher, while ferritin, CRP, and interleukin-6 levels were not. BMIs of patients with hyperglycemia were higher (p = 0.01) but BMI Z-scores were similar (p = 0.055). There was a positive correlation between BMIs and CRP (r: 0.31, p = 0.015). There was a positive correlation between procalcitonin (r: 0.431, p = 0.001) and CRP (r: 0.279, p = 0.029) and maximum PG.

Conclusion Hyperglycemia is a common feature of MIS-C patients and is associated with the severity of the inflammation. As a novel finding, high CRP and procalcitonin should be considered as predictive markers for impaired glucose homeostasis in MIS-C patients.

Keywords

hyperglycemia - multisystem inflammatory syndrome in children - obesity - inflammation - insulin

Publication History

Received: 09 August 2022

Accepted: 13 October 2022

Article published online:
01 December 2022

• References

• 1 Yasuhara J, Kuno T, Takagi H, Sumitomo N. Clinical characteristics of COVID-19 in children: a systematic review. Pediatr Pulmonol 2020; 55 (10) 2565-2575
• 2 Gruber CN, Patel RS, Trachtman R. et al. Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C). Cell 2020; 183 (04) 982-995.e14
• 3 Al-Kuraishy HM, Al-Gareeb AI, Alblihed M, Guerreiro SG, Cruz-Martins N, Batiha GE. COVID-19 in relation to hyperglycemia and diabetes mellitus. Front Cardiovasc Med 2021; 8: 644095
• 4 Sharma RK, Stevens BR, Obukhov AG. et al. ACE2 (angiotensin-converting enzyme 2) in cardiopulmonary diseases: ramifications for the control of SARS-CoV-2. Hypertension 2020; 76 (03) 651-661
• 5 Nakra NA, Blumberg DA, Herrera-Guerra A, Lakshminrusimha S. Multi-system inflammatory syndrome in children (MIS-C) following SARS-CoV-2 infection: review of clinical presentation, hypothetical pathogenesis, and proposed management. Children (Basel) 2020; 7 (07) E69
• 6 Vanderwall C, Eickhoff J, Randall Clark R, Carrel AL. BMI z-score in obese children is a poor predictor of adiposity changes over time. BMC Pediatr 2018; 18 (01) 187
• 7 Bayrakci B. COVID lung: the battlefield. J Pediatr Intensive Care 2021; 10 (01) 1-3
• 8 Feldstein LR, Rose EB, Horwitz SM. et al; Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med 2020; 383 (04) 334-346
• 9 Radia T, Williams N, Agrawal P. et al. Multi-system inflammatory syndrome in children & adolescents (MIS-C): a systematic review of clinical features and presentation. Paediatr Respir Rev 2021; 38: 51-57
• 10 Singh AK, Singh R. Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19. Diabetes Res Clin Pract 2020; 167: 108382
• 11 Tsankov BK, Allaire JM, Irvine MA. et al. Severe COVID-19 infection and pediatric comorbidities: a systematic review and meta-analysis. Int J Infect Dis 2021; 103: 246-256
• 12 Srinivasan V. Stress hyperglycemia in pediatric critical illness: the intensive care unit adds to the stress!. J Diabetes Sci Technol 2012; 6 (01) 37-47
• 13 Garg MK, Gopalakrishnan M, Yadav P, Misra S. Endocrine involvement in COVID-19: mechanisms, clinical features, and implications for care. Indian J Endocrinol Metab 2020; 24 (05) 381-386
• 14 Vanhorebeek I, Gunst J, Van den Berghe G. Critical care management of stress-induced hyperglycemia. Curr Diab Rep 2018; 18 (04) 17
• 15 Finfer S, Chittock DR, Su SY. et al; NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009; 360 (13) 1283-1297
• 16 Vlasselaers D, Milants I, Desmet L. et al. Intensive insulin therapy for patients in paediatric intensive care: a prospective, randomised controlled study. Lancet 2009; 373 (9663): 547-556
• 17 Calcaterra V, Bosoni P, Dilillo D. et al. Impaired glucose-insulin metabolism in multisystem inflammatory syndrome related to SARS-CoV-2 in children. Children (Basel) 2021; 8 (05) 384
• 18 Wallace MD, Metzger NL. Optimizing the treatment of steroid-induced hyperglycemia. Ann Pharmacother 2018; 52 (01) 86-90
• 19 Nowak KM, Rdzanek-Pikus M, Romanowska-Próchnicka K, Nowakowska-Płaza A, Papierska L. High prevalence of steroid-induced glucose intolerance with normal fasting glycaemia during low-dose glucocorticoid therapy: an oral glucose tolerance test screening study. Rheumatology (Oxford) 2021; 60 (06) 2842-2851
• 20 Duru N, van der Goes MC, Jacobs JW. et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013; 72 (12) 1905-1913
• 21 Larsen CM, Faulenbach M, Vaag A. et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356 (15) 1517-1526
• 22 De Spiegeleer M, De Paepe E, Van Meulebroek L, Gies I, De Schepper J, Vanhaecke L. Paediatric obesity: a systematic review and pathway mapping of metabolic alterations underlying early disease processes. Mol Med 2021; 27 (01) 145
• 23 Weiss R, Dziura J, Burgert TS. et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med 2004; 350 (23) 2362-2374
• 24 Acevedo L, Piñeres-Olave BE, Niño-Serna LF. et al. Mortality and clinical characteristics of multisystem inflammatory syndrome in children (MIS-C) associated with covid-19 in critically ill patients: an observational multicenter study (MISCO study). BMC Pediatr 2021; 21 (01) 516
• 25 Godfred-Cato S, Bryant B, Leung J. et al; California MIS-C Response Team. COVID-19-associated multisystem inflammatory syndrome in children—United States, March-July 2020. MMWR Morb Mortal Wkly Rep 2020; 69 (32) 1074-1080
• 26 Naguib MN, Raymond JK, Vidmar AP. New onset diabetes with diabetic ketoacidosis in a child with multisystem inflammatory syndrome due to COVID-19. J Pediatr Endocrinol Metab 2020; 34 (01) 147-150